本文關(guān)鍵詞：CRIPT、FAM82B、RABEP1基因多態(tài)性與精神分裂癥的關(guān)聯(lián)研究及抗精神病藥物對糖脂代謝的影響　出處：《新疆醫(yī)科大學》2014年碩士論文　論文類型：學位論文

  更多相關(guān)文章： 精神分裂癥 基因 單核苷酸多態(tài)性 空腹血糖 血脂

【摘要】：目的：全基因組關(guān)聯(lián)研究發(fā)現(xiàn)RABEP1基因rs1058398和rs1065482、FAM82B基因rs13042和CRIPT基因rs3087822位點的多態(tài)性可能與精神分裂癥有關(guān)聯(lián),但有關(guān)以上基因位點多態(tài)性與精神分裂癥相關(guān)性的研究結(jié)果尚不明確,本研究選取中國漢族人群精神分裂癥患者與正常對照做為研究對象,探討以上三個基因上的4個位點多態(tài)性與中國漢族精神分裂癥患病是否有關(guān)。同時分析比較精神分裂癥患者服用抗精神病藥物治療前后血糖、血脂水平變化,并進一步初探不同位點基因型與糖脂代謝的相關(guān)性。方法：(1)本研究采用病例對照研究,病例組選擇2009年至2013年間江蘇省淮安市第三人民醫(yī)院精神病科的經(jīng)診斷為精神分裂癥住院患者2358例,對照選擇同地區(qū)的社區(qū)健康體檢人員2139例,采用TaqMan探針技術(shù)進行基因分型,比較病例組和對照組基因型和等位基因頻率分布的差異,進一步探討基因-基因的交互作用。(2)比較2013年間江蘇省淮安市第三人民醫(yī)院575例首次入院患者抗精神病藥物治療4周前后GLU、TG、TC、HDL、LDL的變化。(3)選取575例首次入院患者中有基因分型結(jié)果的研究對象,比較不同位點基因型之間糖脂代謝變化。應(yīng)用的統(tǒng)計學方法：t檢驗、單因素方差分析、卡方檢驗、Logistic回歸、叉生分析等。結(jié)果：(1)FAM82B基因的rs13042位點的多態(tài)性與精神分裂癥患病有關(guān),其A等位基因可能是精神分裂癥患病的保護因素(P=1.750x10-7),OR(95%CI)為0.800(0.736-0.870)。CRIPT基因的rs3087822位點的多態(tài)性與精神分裂癥患病有關(guān),其G等位基因可能是精神分裂癥的危險因素(P=3.205×10-5),OR(95%CI)為1.255(1.127-1.397)。(2)抗精神病藥物能引起糖脂代謝紊亂,入院治療后空腹血糖呈降低趨勢(t=4.085,P=5.046×10-5),膽固醇、甘油三酯、低密度脂蛋白均較治療前升高(t=6.123,P=1.704×10-9；t=10.691,P=1.875×10-24t=6.064,P=2.411×10-9)。結(jié)論：FAM82B基因的rs13042位點的A等位基因顯著降低個體罹患精神分裂癥的危險,而CRIPT基因的rs3087822位點的G等位基因會增加個體罹患精神分裂癥危險。服用抗精神病藥物的精神分裂癥新發(fā)病例4周后血糖、血脂發(fā)生變化,提示在臨床治療的過程當中應(yīng)充分重視抗精神病藥物而引起的代謝異常風險增加。
[Abstract]:Objective: a genome-wide association study found that the RABEP1 gene rs1058398 and rs1065482 polymorphism of FAM82B gene rs13042 and CRIPT gene rs3087822 locus may be associated with schizophrenia, but the above gene polymorphism and schizophrenia research results is not clear, this study selected China Han nationality schizophrenic patients and normal controls as the research object, discusses the above three gene 4 polymorphism and China Han schizophrenia. At the same time comparing whether patients with schizophrenia before and after taking antipsychotic drugs in the treatment of blood glucose, blood lipid level changes, and further study on different genotype correlation with glucose and lipid metabolism. Methods: (1) in this study, case-control study, cases from 2009 to 2013 by the Department of psychiatry Huai'an Third People's Hospital of Jiangsu Province A diagnosis of schizophrenia patients in 2358 cases, the control of community health personnel with the area of 2139 cases were genotyped by TaqMan probe technology, compared with the case group and the control group of genotype and allele frequency differences, to further explore the interaction of gene gene. (2) of 2013 years in Jiangsu Huai'an Third People's Hospital, 575 cases of first hospitalization patients treated with antipsychotic drugs before and after 4 weeks of GLU, TG, TC, HDL, LDL. (3) a total of 575 cases of patients admitted to hospital for the first time in the study of genotyping results, glucose and lipid metabolism between different genotypes. The application of statistical Analysis: t test and the single factor variance analysis, chi square test, Logistic regression, crossover analysis. Results: (1) polymorphism and schizophrenia rs13042 locus of FAM82B gene related to the prevalence of the A allele, probably schizophrenia The protection factor for disease (P=1.750x10-7), OR (95%CI) 0.800 (0.736-0.870) polymorphisms and schizophrenia rs3087822 loci of.CRIPT gene related to the prevalence of risk factors, the G allele may be schizophrenia (P=3.205 * 10-5), OR (95%CI) 1.255 (1.127-1.397) (2). Antipsychotic drugs can cause lipid metabolic disorders, hospital treatment after fasting blood glucose decreased (t=4.085, P=5.046 * 10-5), cholesterol, triglyceride, low density lipoprotein were significantly higher than before treatment (t=6.123, P=1.704 * 10-9; t=10.691 P=, 1.875 * 10-24t=6.064, P=2.411 * 10-9). Conclusion: the rs13042 locus of FAM82B gene the A allele significantly lower risk individuals with schizophrenia, and rs3087822 sites of CRIPT gene G allele may increase individual schizophrenia risk. Taking antipsychotic drugs for schizophrenia cases after 4 weeks of blood glucose The changes in blood lipids suggest that in the course of clinical treatment, attention should be paid to the increased metabolic risk caused by antipsychotic drugs.

【學位授予單位】：新疆醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R749.3

【參考文獻】

相關(guān)期刊論文 前10條

1 李大奇;蘇華龍;吳勝;;648例首發(fā)精神分裂癥用藥情況[J];第三軍醫(yī)大學學報;2011年06期

2 戴亞美;多基因遺傳病易感基因的遺傳定位[J];國外醫(yī)學.遺傳學分冊;1999年06期

3 陶世武;楊誠;陳強;潘潤德;潘天偉;李梁;周偉東;;4種非典型抗精神病藥物對精神分裂癥患者血糖及血脂代謝的影響[J];廣西醫(yī)學;2009年09期

4 沈文龍;李晨虎;饒順曾;占歸來;張紅;;精神分裂癥患者伴發(fā)代謝綜合征的患病率調(diào)查[J];神經(jīng)疾病與精神衛(wèi)生;2007年06期

5 趙慶蓮;任巧玲;侯峰;楊秋蘭;張曉艷;;新型抗精神病藥對精神病患者體重及血糖、血脂水平的影響[J];神經(jīng)疾病與精神衛(wèi)生;2008年05期

6 劉燕,李華芳,王慧芳,王克勛,高哲石,顧牛范;氯氮平、利培酮對精神分裂癥病人血糖-胰島素穩(wěn)態(tài)的影響及相關(guān)因素分析[J];上海精神醫(yī)學;2003年05期

7 方澤忠;連國民;;五種非典型抗精神病藥物對血糖及血脂水平影響的對照研究[J];浙江臨床醫(yī)學;2008年03期

8 徐繼華;;抗精神病藥物對精神分裂癥患者血脂水平的影響分析[J];檢驗醫(yī)學與臨床;2013年12期

9 陳修哲;楊曉華;陳建平;高蕊;楊曉東;郝維德;;抗精神病藥物對精神分裂癥患者血脂、血糖和體重影響的研究[J];山東精神醫(yī)學;2006年01期

10 蔡松濤;何蓮珠;劉文亮;張金玲;;抗精神病藥對精神分裂癥患者體質(zhì)量、血糖的影響[J];汕頭大學醫(yī)學院學報;2012年03期

，

本文編號：1414594